Roussel Uclaf

About: Roussel Uclaf is a based out in . It is known for research contribution in the topics: Alkyl & Alkoxy group. The organization has 1888 authors who have published 2338 publications receiving 36508 citations.

3-cycloalkyl-propanamides

Abstract: A compound selected from the group consisting of all tautomeric forms of a cycloalky-propanamide of the formula ##STR1## wherein R 1 is cycloalkyl of 3 to 6 carbon atoms, R 2 is hydrogen or alkyl of 1 to 3 carbon atoms, R 3 , R 4 , R 5 , R 6 and R 7 are individually selected from the group consisting of hydrogen, halogen, --NO 2 , azido, --CN, alkyl, alkoxy and alkylthio of 1 to 6 carbon atoms, --(CH 2 ) m --CF 3 , --O--(CH 2 ) m --CF 3 , --S--(CH 2 ) m --CF 3 , m is an integer from 0 to 3, --CF 2 --Hal, --OCF 2 --Hal, ##STR2## n is an integer from 1 to 3, Hal, Hal 1 , Hal 2 and Hal 3 are individually halogen, and --COR', R' is --OH or alkyl or alkoxy of 1 to 3 carbon atoms or R 4 and R 5 together are --O--CH 2 --O-- and their non-toxic, pharmaceutically acceptable basic salts having anti-inflammatory activity.

Novel trifluoromethyl-quinolines

Abstract: 7- OR 8-TRIFLUOROMETHYL-QUINOLINES OF THE FORMULA WHEREIN N IS 1 OR 2 AND R is selected from the group consisting of saturated and unsaturated heterocyclic having an oxygen atom, a nitrogen atom or both a nitrogen and oxygen atom and their non-toxic, pharmaceutically acceptable acid addition salts having analgesic and anti-inflammatory activity and their preparation.

Pharmacokinetics of cefodizime following single doses of 0.5, 1.0, 2.0, and 3.0 grams administered intravenously to healthy volunteers.

Abstract: Cefodizime is a new expanded-spectrum cephalosporin for parenteral use which possesses a broad antibacterial spectrum and potent antibacterial activity and is stable against most beta-lactamases. The aim of this study was to assess the pharmacokinetics of cefodizime, administered intravenously, over the dose range of 0.5 to 3.0 g in healthy volunteers. Concentrations of cefodizime in the serum and urine were determined by high-performance liquid chromatography. The area under the concentration-time curve from 0 h to infinity and the amount of drug excreted in urine from 0 to 34 h increased in a linear, dose-dependent manner with increasing doses of antibiotic from 0.5 to 3.0 g. Mean concentrations of cefodizime in plasma at the end of infusion increased from 97 to 440 mg liter-1 over the dose range 0.5 to 3.0 g and displayed a slight deviation from linearity at doses in excess of 2.0 g. Total plasma clearance (3.11 liters h-1), volume of distribution at steady state (10.5 liters), terminal elimination half-life (3.3 h), and renal clearance (1.91 liters h-1) remained constant over the doses administered. Cefodizime was well tolerated in this study.